Axsome Therapeutics
AXSMAxsome Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders.
Earnings
Q3 2026 report
November 2, 2026Next report
Date not yet announcedValuation & ratios
Valuation
Competitors
By market cap
By revenue growth
By net margin
Profile
Axsome Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders. The company leverages proprietary medicinal chemistry and formulation technologies to address significant gaps in care for psychiatric and neurological conditions. Its value proposition is centered on delivering differentiated products with novel mechanisms of action to transform patient outcomes in underserved therapeutic segments.
Axsome is a commercial-stage biopharmaceutical company with a growing portfolio of approved CNS drugs and a late-stage pipeline utilizing the 505(b)(2) regulatory pathway to reduce development risk.
FAQ
- What is Axsome Therapeutics's market cap?
- Axsome Therapeutics (AXSM) has a market capitalization of $7.5B and trades on NASDAQ.
- What is Axsome Therapeutics's revenue and profitability?
- Axsome Therapeutics generated $776.6M in trailing twelve-month revenue with a net loss of $191.6M, representing a net margin of -24.7%. Gross margin stands at 93.2%, with free cash flow of -$72.9M. The latest reported period is FQ2_2026.
- Who are Axsome Therapeutics's competitors?
- Axsome Therapeutics's key competitors include Harmony Biosciences LLC, Alkermes Inc. plc, AbbVie Inc., and others. These companies compete in similar markets and product categories.
- Who does Axsome Therapeutics partner with?
- Axsome Therapeutics's notable partners include Pfizer Inc., Jazz Pharmaceuticals plc, Atnahs Pharma UK Limited (Pharmanovia), and others.
- What subsidiaries does Axsome Therapeutics have?
- Axsome Therapeutics's subsidiaries include Baergic Bio, Inc..
- Where is Axsome Therapeutics headquartered?
- Axsome Therapeutics is headquartered in United States of America and employs approximately 569 people. It has been publicly traded since 2015.
